{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:02:50Z","timestamp":1791270170863,"version":"4.1.0"},"reference-count":176,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":3520,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s13311-013-0238-x","type":"journal-article","created":{"date-parts":[[2013,11,27]],"date-time":"2013-11-27T17:11:39Z","timestamp":1385572299000},"page":"78-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson's Disease"],"prefix":"10.1016","volume":"11","author":[{"given":"Barbara","family":"Connolly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-013-0238-x_bib1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1212\/WNL.0b013e31829c5c86","article-title":"Evolution of mild cognitive impairment in Parkinson disease","volume":"81","author":"Broeders","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/mds.25426","article-title":"Measuring mild cognitive impairment in patients with Parkinson's disease","volume":"28","author":"Marras","year":"2013","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib3","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/mds.23823","article-title":"MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI","volume":"26","author":"Litvan","year":"2011","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib5","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/01.wnl.0000180516.69442.95","article-title":"Cognitive profile of patients with newly diagnosed Parkinson disease","volume":"65","author":"Muslimovic","year":"2005","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib6","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mds.20974","article-title":"Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia","volume":"21","author":"Janvin","year":"2006","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib7","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1093\/brain\/awp245","article-title":"The distinct cognitive syndromes of Parkinson's disease: 5\u00a0year follow-up of the CamPaIGN cohort","volume":"132","author":"Williams-Gray","year":"2009","journal-title":"Brain"},{"key":"10.1007\/s13311-013-0238-x_bib8","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson's disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib9","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies - Third report of the DLB consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1474-4422(03)00619-7","article-title":"Dementia with Lewy bodies","volume":"3","author":"McKeith","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/0891988712464823","article-title":"Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden","volume":"25","author":"Leroi","year":"2012","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib12","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/mds.23664","article-title":"Parkinson's disease: the quintessential neuropsychiatric disorder","volume":"26","author":"Weintraub","year":"2011","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib13","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1212\/WNL.0b013e3181bf992f","article-title":"Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort","volume":"73","author":"Uc","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib14","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1586\/ern.12.131","article-title":"Neurobiology of cognitive impairment in Parkinson's disease","volume":"12","author":"Jellinger","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"10.1007\/s13311-013-0238-x_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/01.wnf.0000172498.24770.54","article-title":"Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease - A pilot study","volume":"28","author":"Linazasoro","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0238-x_bib16","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/mds.23738","article-title":"The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study","volume":"26","author":"Hanagasi","year":"2011","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/mds.22307","article-title":"Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study","volume":"24","author":"Marsh","year":"2009","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib18","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.0b013e3181ebdd79","article-title":"Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease","volume":"75","author":"Weintraub","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00002826-200601000-00005","article-title":"Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease - A pilot study","volume":"29","author":"Auriel","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0238-x_bib20","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.0b013e3182143537","article-title":"Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial","volume":"76","author":"Espay","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(12)70106-0","article-title":"Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial","volume":"11","author":"Moreau","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/1533317511424892","article-title":"Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis","volume":"26","author":"Weintraub","year":"2011","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1007\/s13311-013-0238-x_bib23","article-title":"Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease","volume":"3","author":"Rolinski","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-013-0238-x_bib24","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-013-0238-x_bib25","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000184517.69816.e9","article-title":"Benefits of rivastigmine on attention in dementia associated with Parkinson disease","volume":"65","author":"Wesnes","year":"2005","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib26","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1755-5949.2010.00182.x","article-title":"Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia","volume":"16","author":"Schmitt","year":"2010","journal-title":"CNS Neurosci Ther"},{"key":"10.1007\/s13311-013-0238-x_bib27","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1159\/000305100","article-title":"Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living","volume":"29","author":"Olin","year":"2010","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1007\/s13311-013-0238-x_bib28","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","article-title":"Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study","volume":"356","author":"McKeith","year":"2000","journal-title":"Lancet"},{"key":"10.1007\/s13311-013-0238-x_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00002018-200831010-00007","article-title":"Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia \u2013 a retrospective analysis of a double-blind trial and an open- label extension","volume":"31","author":"Oertel","year":"2008","journal-title":"Drug Saf"},{"key":"10.1007\/s13311-013-0238-x_bib30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1742-1241.2009.02253.x","article-title":"Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials","volume":"64","author":"Sadowsky","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1007\/s13311-013-0238-x_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000098335","article-title":"Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies","volume":"23","author":"Rowan","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1007\/s13311-013-0238-x_bib32","first-page":"30","article-title":"The DONPAD-study\u2013treatment of dementia in patients with Parkinson's disease with donepezil","volume":"27","author":"Muller","year":"2006","journal-title":"J Neural Transm Suppl"},{"key":"10.1007\/s13311-013-0238-x_bib33","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","article-title":"Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study","volume":"76","author":"Ravina","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gps.993","article-title":"Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease","volume":"19","author":"Leroi","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib35","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/jnnp.72.6.708","article-title":"Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study","volume":"72","author":"Aarsland","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib36","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/mds.25098","article-title":"Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study","volume":"27","author":"Dubois","year":"2012","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.23557","article-title":"Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial","volume":"72","author":"Mori","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib38","first-page":"25","article-title":"Efficacy and safety of galantamine (Reminyl) in the treatment of dementia in patients with Parkinson's disease (Open-label controlled trial)","volume":"107","author":"Litvinenko","year":"2007","journal-title":"Z Nevrol Psikhiatrii Im Ss Ko"},{"key":"10.1007\/s13311-013-0238-x_bib39","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.949","article-title":"Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia","volume":"18","author":"Aarsland","year":"2003","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib40","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","article-title":"Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Emre","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","article-title":"Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo- controlled, multicentre trial","volume":"8","author":"Aarsland","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib42","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/mds.22495","article-title":"Randomized controlled trial of memantine in dementia associated with Parkinson's disease","volume":"24","author":"Leroi","year":"2009","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib43","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/mds.25457","article-title":"Improving memory in Parkinson's disease: a healthy brain ageing cognitive training program","volume":"28","author":"Naismith","year":"2013","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib44","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/mds.25377","article-title":"Nonpharmacological enhancement of cognitive function in Parkinson's disease: a systematic review","volume":"28","author":"Hindle","year":"2013","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib45","first-page":"1154","article-title":"Practice parameter: management of dementia (an evidence-based review)","volume":"56","author":"Doody","year":"2001","journal-title":"Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15\u00a0years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib47","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/mds.22839","article-title":"The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria","volume":"25","author":"Fenelon","year":"2010","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib48","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1155\/2013\/645429","article-title":"Parkinson disease psychosis: update","volume":"27","author":"Friedman","year":"2013","journal-title":"Behav Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib49","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00415-010-5786-y","article-title":"Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease","volume":"258","author":"Gomez-Esteban","year":"2011","journal-title":"J Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib50","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1532-5415.2000.tb06891.x","article-title":"Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study","volume":"48","author":"Aarsland","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"10.1007\/s13311-013-0238-x_bib51","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","article-title":"A 12-year population-based study of psychosis in Parkinson disease","volume":"67","author":"Forsaa","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","article-title":"The epidemiology of dementia associated with Parkinson disease","volume":"289","author":"Aarsland","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-013-0238-x_bib53","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1176\/appi.neuropsych.10070109","article-title":"Underlying neurobiology and clinical correlates of mania status after subthalamic nucleus deep brain stimulation in Parkinson's disease: a review of the literature","volume":"24","author":"Chopra","year":"2012","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1007\/s13311-013-0238-x_bib54","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/13554794.2011.568502","article-title":"Pharmacological treatment of deep brain stimulation-induced hypomania leads to clinical remission while preserving motor benefits","volume":"18","author":"Schilbach","year":"2012","journal-title":"Neurocase"},{"key":"10.1007\/s13311-013-0238-x_bib55","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neubiorev.2007.07.012","article-title":"The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations","volume":"32","author":"Allen","year":"2008","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1007\/s13311-013-0238-x_bib56","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/brain\/awf033","article-title":"Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe","volume":"125","author":"Harding","year":"2002","journal-title":"Brain"},{"key":"10.1007\/s13311-013-0238-x_bib57","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.parkreldis.2008.05.007","article-title":"Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease","volume":"15","author":"Kalaitzakis","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-013-0238-x_bib58","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/archneur.64.7.984","article-title":"Metabolic alterations in patients with Parkinson disease and visual hallucinations","volume":"64","author":"Boecker","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib59","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1093\/brain\/awp223","article-title":"Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations","volume":"132","author":"Meppelink","year":"2009","journal-title":"Brain"},{"key":"10.1007\/s13311-013-0238-x_bib60","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in Parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib61","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1517\/14656566.2011.587122","article-title":"An update expert opinion on management and research strategies in Parkinson's disease psychosis","volume":"12","author":"Goldman","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1007\/s13311-013-0238-x_bib62","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(94)92114-8","article-title":"Risperidone in Parkinson's disease","volume":"344","author":"Ford","year":"1994","journal-title":"Lancet"},{"key":"10.1007\/s13311-013-0238-x_bib63","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/mds.1258","article-title":"Risperidone and Parkinson's disease","volume":"17","author":"Factor","year":"2002","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib64","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","article-title":"Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease","volume":"52","author":"Breier","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib65","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/mds.10217","article-title":"Olanzapine treatment for dopaminergic-induced hallucinations","volume":"17","author":"Ondo","year":"2002","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib66","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/WNF.0b013e31824d5115","article-title":"Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial","volume":"35","author":"Pintor","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0238-x_bib67","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clineuro.2006.07.003","article-title":"Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off- periods and pathological laughing","volume":"109","author":"Schindehutte","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1007\/s13311-013-0238-x_bib68","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/0897190011426556","article-title":"Atypical antipsychotic drugs in the treatment of Parkinson's disease","volume":"24","author":"Friedman","year":"2011","journal-title":"J Pharm Pract"},{"key":"10.1007\/s13311-013-0238-x_bib69","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/mds.21091","article-title":"Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease","volume":"21","author":"Friedman","year":"2006","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib70","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q","article-title":"Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12\u00a0week open label extension in the PSYCLOPS trial","volume":"16","author":"Factor","year":"2001","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib71","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib72","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","article-title":"Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease","volume":"20","author":"Ondo","year":"2005","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib73","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","article-title":"Effect of quetiapine a double-blind in psychotic Parkinson's disease patients: labeled study of 3\u00a0months' duration","volume":"22","author":"Rabey","year":"2007","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib74","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.3109\/00207450903222758","article-title":"Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study","volume":"119","author":"Fernandez","year":"2009","journal-title":"Int J Neurosci"},{"key":"10.1007\/s13311-013-0238-x_bib75","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":"Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis","volume":"27","author":"Morgante","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0238-x_bib76","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":"Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis","volume":"29","author":"Merims","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0238-x_bib77","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-013-0238-x_bib78","first-page":"S170","article-title":"Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP-103-020)","volume":"28","author":"Cummings","year":"2013","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib79","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","article-title":"Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease","volume":"21","author":"Burn","year":"2006","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib80","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/mds.24996","article-title":"Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease","volume":"27","author":"Postuma","year":"2012","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib81","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/archneurol.2008.561","article-title":"Overview of the extranigral aspects of Parkinson disease","volume":"66","author":"Lim","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib82","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0735-6757(00)90023-8","article-title":"Emergency department presentations of patients with Parkinson's disease","volume":"18","author":"Factor","year":"2000","journal-title":"Am J Emerg Med"},{"key":"10.1007\/s13311-013-0238-x_bib83","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1600-0404.2004.00292.x","article-title":"Mortality in Parkinson's disease and its association with dementia and depression","volume":"110","author":"Hughes","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-013-0238-x_bib84","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/jnnp.69.3.308","article-title":"What contributes to quality of life in patients with Parkinson's disease?","volume":"69","author":"Schrag","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib85","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/1359105311428537","article-title":"The relationship of depression and disease stage to patient perceptions of Parkinson's disease","volume":"17","author":"Hurt","year":"2012","journal-title":"J Health Psychol"},{"key":"10.1007\/s13311-013-0238-x_bib86","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00415-009-0146-5","article-title":"Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia","volume":"256","author":"Santangelo","year":"2009","journal-title":"J Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib87","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1212\/01.wnl.0000268695.63392.10","article-title":"The impact of depressive symptoms in early Parkinson disease","volume":"69","author":"Ravina","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib88","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1600-0404.2010.01332.x","article-title":"Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson's disease: the Norwegian ParkWest study","volume":"122","author":"Leiknes","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-013-0238-x_bib89","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","article-title":"The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease","volume":"26","author":"Seppi","year":"2011","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib90","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S1353-8020(11)70024-4","article-title":"Mood disorders in Parkinson's disease","volume":"18","author":"Tan","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-013-0238-x_bib91","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson's disease","volume":"23","author":"Reijnders","year":"2008","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib92","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/gps.1456","article-title":"Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease","volume":"21","author":"Ehrt","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib93","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jns.2011.07.007","article-title":"Prevalence of depression in Parkinson's disease: effects of disease stage, motor subtype and gender","volume":"310","author":"van der Hoek","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-013-0238-x_bib94","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrneurol.2011.189","article-title":"Depression in Parkinson disease\u2013epidemiology, mechanisms and management","volume":"8","author":"Aarsland","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib95","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.0b013e318285c0ed","article-title":"Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications","volume":"80","author":"Storch","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib96","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1468-1331.2003.00612.x","article-title":"Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study","volume":"10","author":"Rektorova","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib97","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double- blind, placebo-controlled trial","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib98","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","article-title":"Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study","volume":"253","author":"Barone","year":"2006","journal-title":"J Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib99","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/11585380-000000000-00000","article-title":"The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review","volume":"71","author":"Leentjens","year":"2011","journal-title":"Drugs"},{"key":"10.1007\/s13311-013-0238-x_bib100","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.parkreldis.2013.02.018","article-title":"Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER","volume":"19","author":"Ray","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-013-0238-x_bib101","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0269881113478282","article-title":"Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis","volume":"27","author":"Rocha","year":"2013","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-013-0238-x_bib102","first-page":"201","article-title":"Comparison of sertraline and venlafaxine treatments for depression in Parkinson's disease","volume":"48","author":"Akca","year":"2011","journal-title":"Noropsikiyatri Arsivi"},{"key":"10.1007\/s13311-013-0238-x_bib103","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","article-title":"A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease","volume":"78","author":"Richard","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib104","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib105","first-page":"163","article-title":"Depression in idiopathic Parkinson's disease treated with citalopram: A placebo-controlled trial","volume":"XXX","author":"Wermuth","year":"1998"},{"key":"10.1007\/s13311-013-0238-x_bib106","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/gps.865","article-title":"SSRIs in the treatment of depression in Parkinson's disease","volume":"18","author":"Leentjens","year":"2003","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib107","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mds.21966","article-title":"Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Devos","year":"2008","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib108","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2377-10-49","article-title":"Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials - art. no. 49","volume":"10","author":"Skapinakis","year":"2010","journal-title":"BMC Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib109","series-title":"Monoamine oxidase inhibitors and tricyclic antidepressants. Mood disorders: a practical guide","author":"Ghaemi","year":"2008"},{"key":"10.1007\/s13311-013-0238-x_bib110","first-page":"S205","article-title":"Efficacy, tolerability, and safety of mirtazapine in the treatment of major depressive disorder due to Parkinson's disease","volume":"19","author":"Weiser","year":"2004","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib111","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1041610210001687","article-title":"Bupropion in the treatment of depression in Parkinson's disease","volume":"23","author":"Zaluska","year":"2011","journal-title":"Int Psychogeriatr"},{"key":"10.1007\/s13311-013-0238-x_bib112","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.mehy.2010.07.024","article-title":"Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments","volume":"75","author":"Raskin","year":"2010","journal-title":"Med Hypotheses"},{"key":"10.1007\/s13311-013-0238-x_bib113","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4088\/JCP.v63n0405","article-title":"Effect of reboxetine on depression in Parkinson's disease patients","volume":"63","author":"Lemke","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib114","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.48.4.1070","article-title":"Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease","volume":"48","author":"Richard","year":"1997","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.parkreldis.2010.12.003","article-title":"Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial","volume":"17","author":"Ondo","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-013-0238-x_bib116","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/jnnp.2004.042291","article-title":"Cognitive behavioural therapy (CBT) for carers of patients with Parkinson's disease: a preliminary randomised controlled trial","volume":"76","author":"Secker","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib117","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1176\/appi.ajp.2011.10111669","article-title":"Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial","volume":"168","author":"Dobkin","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib118","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0891988711422529","article-title":"Telephone-based cognitive-behavioral therapy for depression in Parkinson disease","volume":"24","author":"Dobkin","year":"2011","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib119","first-page":"201","article-title":"Dysarthria during ECT given for Parkinson's disease and depression","volume":"8","author":"Holzer","year":"1992","journal-title":"Convuls Ther"},{"key":"10.1007\/s13311-013-0238-x_bib120","first-page":"204","article-title":"Electroconvulsive therapy in Parkinson's disease: a report on five cases","volume":"8","author":"Friedman","year":"1992","journal-title":"Convuls Ther"},{"key":"10.1007\/s13311-013-0238-x_bib121","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/YCT.0b013e318154b993","article-title":"Bitemporal electroconvulsive therapy for depression in a Parkinson disease patient with a deep-brain stimulator","volume":"24","author":"Bailine","year":"2008","journal-title":"J Ect"},{"key":"10.1007\/s13311-013-0238-x_bib122","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mds.22833","article-title":"Anxiety disorders in Parkinson's disease: prevalence and risk factors","volume":"25","author":"Dissanayaka","year":"2010","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib123","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1212\/WNL.62.6_suppl_4.S12","article-title":"Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease","volume":"62","author":"Factor","year":"2004","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib124","doi-asserted-by":"crossref","first-page":"d1199","DOI":"10.1136\/bmj.d1199","article-title":"Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis","volume":"342","author":"Baldwin","year":"2011","journal-title":"BMJ"},{"key":"10.1007\/s13311-013-0238-x_bib125","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1155\/2013\/851890","article-title":"Apathy in Parkinson's disease: diagnosis, neuropsychological correlates, pathophysiology and treatment","volume":"27","author":"Santangelo","year":"2013","journal-title":"Behav Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib126","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1037\/a0019650","article-title":"The independent influence of apathy and depression on cognitive functioning in Parkinson's disease","volume":"24","author":"Butterfield","year":"2010","journal-title":"Neuropsychology"},{"key":"10.1007\/s13311-013-0238-x_bib127","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","article-title":"The Priamo study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease","volume":"24","author":"Barone","year":"2009","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib128","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/mds.22843","article-title":"Apathy may herald cognitive decline and dementia in Parkinson's disease","volume":"24","author":"Dujardin","year":"2009","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib129","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/0891988713481267","article-title":"Apathy in patients with Parkinson disease as a function of side of onset","volume":"26","author":"Harris","year":"2013","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.parkreldis.2010.12.011","article-title":"The trajectory of apathy after deep brain stimulation: from pre-surgery to 6\u00a0months post-surgery in Parkinson's disease","volume":"17","author":"Kirsch-Darrow","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-013-0238-x_bib131","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0028-3932(02)00108-2","article-title":"Motivation, reward, and Parkinson's disease: influence of dopatherapy","volume":"40","author":"Czernecki","year":"2002","journal-title":"Neuropsychologia"},{"key":"10.1007\/s13311-013-0238-x_bib132","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/mds.21949","article-title":"Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom","volume":"23","author":"Czernecki","year":"2008","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib133","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/mds.22505","article-title":"Impulsive and compulsive behaviors in Parkinson's disease","volume":"24","author":"Evans","year":"2009","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib134","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1756285613476127","article-title":"Diagnosis and treatment of impulse control disorders in patients with movement disorders","volume":"6","author":"Mestre","year":"2013","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-013-0238-x_bib135","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease a cross- sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib136","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/WNF.0b013e31826e6e6d","article-title":"Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease","volume":"35","author":"Perez-Lloret","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0238-x_bib137","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S1353-8020(09)70847-8","article-title":"Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management","volume":"15","author":"Ceravolo","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-013-0238-x_bib138","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1212\/WNL.0b013e31827b915c","article-title":"Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study","volume":"80","author":"Weintraub","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib139","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/JCP.0b013e3182979830","article-title":"A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs","volume":"33","author":"Poletti","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-013-0238-x_bib140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archneurol.2009.294","article-title":"Dopamine Agonist withdrawal syndrome in Parkinson disease","volume":"67","author":"Rabinak","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib141","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/jnnp-2012-302684","article-title":"Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic","volume":"84","author":"Pondal","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib142","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ana.22029","article-title":"Pathological gambling in Parkinson disease is reduced by amantadine","volume":"68","author":"Thomas","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib143","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.22164","article-title":"Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study","volume":"68","author":"Weintraub","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib144","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00415-010-5603-7","article-title":"Zonisamide in managing impulse control disorders in Parkinson's disease","volume":"257","author":"Bermejo","year":"2010","journal-title":"J Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib145","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/01.mjt.0000151861.59698.26","article-title":"Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study","volume":"12","author":"Ivanco","year":"2005","journal-title":"Am J Ther"},{"key":"10.1007\/s13311-013-0238-x_bib146","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/JCP.0b013e31802e98c3","article-title":"Quetiapine in a case with Parkinson disease and pathological gambling","volume":"27","author":"Sevincok","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-013-0238-x_bib147","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/mds.23177","article-title":"Clozapine for medication-related pathological gambling in Parkinson disease","volume":"25","author":"Rotondo","year":"2010","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib148","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mds.870130302","article-title":"Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience","volume":"13","author":"Trosch","year":"1998","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib149","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.parkreldis.2005.06.005","article-title":"Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy","volume":"11","author":"Klos","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-013-0238-x_bib150","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.parkreldis.2007.11.008","article-title":"Topiramate in managing impulse control disorders in Parkinson's disease","volume":"14","author":"Bermejo","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1007\/s13311-013-0238-x_bib151","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/WNF.0b013e31824d529b","article-title":"Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease","volume":"35","author":"Bosco","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0238-x_bib152","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/JCP.0b013e3182549c2a","article-title":"Finasteride attenuates pathological gambling in patients with Parkinson disease","volume":"32","author":"Bortolato","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-013-0238-x_bib153","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1017\/S104161020300886X","article-title":"Low-dose cyproterone acetate treatment of sexual acting out in men with dementia","volume":"15","author":"Haussermann","year":"2003","journal-title":"Int Psychogeriatr"},{"key":"10.1007\/s13311-013-0238-x_bib154","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.21770","article-title":"Long-term follow-up of impulse control disorders in Parkinson's disease","volume":"23","author":"Mamikonyan","year":"2008","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib155","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mds.10625","article-title":"Disabling repetitive behaviors in Parkinson's disease","volume":"19","author":"Kurlan","year":"2004","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib156","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00002826-200105000-00009","article-title":"Pathologic gambling in patients with Parkinson's disease","volume":"24","author":"Gschwandtner","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-013-0238-x_bib157","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/1520-6394(2000)11:4<185::AID-DA8>3.0.CO;2-H","article-title":"Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents","volume":"11","author":"Seedat","year":"2000","journal-title":"Depress Anxiety"},{"key":"10.1007\/s13311-013-0238-x_bib158","first-page":"S141","article-title":"Randomized, double-blind, placebo-controlled study of naltrexone for impulse control disorders in Parkinson's disease","volume":"28","author":"Weintraub","year":"2013","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib159","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00023210-200923020-00005","article-title":"Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management","volume":"23","author":"O'Sullivan","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-013-0238-x_bib160","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1212\/01.wnl.0000184487.72289.f0","article-title":"Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease","volume":"65","author":"Evans","year":"2005","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib161","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","article-title":"Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies","volume":"68","author":"Giovannoni","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib162","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00415-012-6669-1","article-title":"Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease","volume":"260","author":"Sriram","year":"2013","journal-title":"J Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib163","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1196\/annals.1444.006","article-title":"Impulse control and related disorders in Parkinson's disease: review","volume":"1142","author":"Lim","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-013-0238-x_bib164","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mds.21780","article-title":"Amantadine may reverse punding in Parkinson's disease - observation in a patient","volume":"23","author":"Kashihara","year":"2008","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib165","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/13554794.2012.713490","article-title":"Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson's disease","volume":"19","author":"Hardwick","year":"2013","journal-title":"Neurocase"},{"key":"10.1007\/s13311-013-0238-x_bib166","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.20045","article-title":"Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome","volume":"19","author":"Evans","year":"2004","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib167","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s00415-010-5817-8","article-title":"Management of punding in Parkinson's disease: an open-label prospective study","volume":"258","author":"Fasano","year":"2011","journal-title":"J Neurol"},{"key":"10.1007\/s13311-013-0238-x_bib168","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1212\/WNL.0b013e3182840678","article-title":"Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers","volume":"80","author":"Okai","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0238-x_bib169","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/mds.21098","article-title":"Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation","volume":"21","author":"Ardouin","year":"2006","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0238-x_bib170","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/jnnp-2012-302387","article-title":"Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease","volume":"84","author":"Eusebio","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib171","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/jnnp.2006.102061","article-title":"Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease","volume":"78","author":"Smeding","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-013-0238-x_bib172","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jocn.2008.12.010","article-title":"Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease","volume":"16","author":"Lim","year":"2009","journal-title":"J Clin Neurosci"},{"key":"10.1007\/s13311-013-0238-x_bib173","first-page":"757","article-title":"The Parkinson Study Group","volume":"340","author":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-013-0238-x_bib174","first-page":"2041","article-title":"The French Clozapine Parkinson Study Group","volume":"53","author":"Clozapine in drug-induced psychosis in Parkinson's disease","year":"1999","journal-title":"Lancet"},{"key":"10.1007\/s13311-013-0238-x_bib175","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/01.jcp.0000088908.24613.db","article-title":"Does nefazodone improve both depression and Parkinson's disease? A pilot randomized trial","volume":"23","author":"Avila","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-013-0238-x_bib176","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/mds.20895","article-title":"Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life","volume":"21","author":"Antonini","year":"2006","journal-title":"Mov Disord"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0238-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-013-0238-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0238-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:10:48Z","timestamp":1761808248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923016392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":176,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1878747923016392"],"URL":"https:\/\/doi.org\/10.1007\/s13311-013-0238-x","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson's Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-013-0238-x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}